Global Targeted Sequencing and Resequencing Market 2024–2033

Reports Description

As per the current market research conducted by CMI Team, the global Targeted Sequencing and Resequencing Market is expected to record a CAGR of 23.1% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD  6.2 Billion. By 2032, the valuation is anticipated to reach USD 91.1 billion.

The Targeted Sequencing and Resequencing Market involves techniques that selectively analyze specific genomic regions, rather than entire genomes, making it a cost-effective and focused approach for genomics research and clinical diagnostics. Its nature is characterized by precision, enabling the identification of genetic variations and mutations.

Current trends in the market include the expansion of clinical applications, improved data analysis tools, growing adoption of long-read sequencing, and the integration of sequencing into fields like oncology, rare disease diagnostics, and population genetics, driving its continuous evolution and demand.

Targeted Sequencing and Resequencing Market – Significant Growth Factors

The Targeted Sequencing and Resequencing Market presents significant growth opportunities due to several factors:

• Personalized Medicine: The growing demand for personalized treatment strategies is a major driver. Targeted sequencing allows for the identification of specific genetic variations, offering tailored therapies and treatment plans for patients.

• Cancer Genomics: Targeted sequencing presents opportunities to detect cancer-related mutations, aiding in early diagnosis and therapy selection, ultimately improving patient outcomes.

• Rare Disease Diagnostics: This technology can uncover rare genetic mutations responsible for many rare diseases, offering new opportunities for diagnosis and potential treatments.

• Agricultural Genomics: Targeted sequencing is employed in agriculture to enhance crop breeding and improve livestock genetics, addressing global food security challenges.

• Population Genetics: Opportunities arise in population genetics research, enabling the study of genetic variations in large populations to understand diseases’ prevalence and evolution.
• Non-Invasive Prenatal Testing (NIPT): Targeted sequencing is a driver for NIPT, offering non-invasive screening for fetal genetic abnormalities and chromosomal disorders, and providing safer alternatives to traditional invasive methods. These drivers and opportunities collectively stimulate innovation and growth in the Targeted Sequencing and sequencing market.

Targeted Sequencing and Resequencing Market – Mergers and Acquisitions

The Targeted Sequencing and sequencing market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their Type offerings and profitability. Some notable examples of mergers and acquisitions in the Targeted Sequencing and Resequencing Market include:

• During the Illumina Genomics Forum in October 2022, the NovaSeq X was unveiled, a groundbreaking platform capable of processing approximately 20,000 whole genomes annually. This innovative technology incorporates an astonishing 10 billion flow cells and generates a substantial 6 TB of data when operated with 2150 base pair reads.

• In December 2021, F. Hoffmann-La Roche AG introduced the AVENIO Edge System, designed to optimize the automation and processing of NGS samples. This system plays a pivotal role in advancing the field of precision medicine.

These mergers and acquisitions have helped companies expand their Type offerings, improve their market presence, and capitalize on growth opportunities in the Targeted Sequencing and Resequencing Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Targeted Sequencing and Resequencing Market	Pediatric Supplements Market	Forensic Lab Equipment Market
CAGR 23.1% (Approx)	CAGR 6.7% (Approx)	CAGR 7.7% (Approx)
USD 91.1 Billlion by 2032	USD 6.77 Billion by 2032	USD 21.1 Billion by 2032

Targeted Sequencing and Resequencing Market – Significant Threats

The Targeted Sequencing and Resequencing Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Technological Obsolescence: Rapid advancements in sequencing technologies can render existing platforms and methods obsolete, necessitating continuous investment in updating equipment and techniques.

• Data Security Concerns: With the increasing volume of genetic data generated, there is a heightened risk of data breaches and privacy concerns, potentially undermining public trust and regulatory support.

• Regulatory Challenges: Evolving and complex regulations governing genomic data and clinical applications can create hurdles for market players, leading to delays and compliance issues.

• Competitive Landscape: Intense competition in the genomics sector may lead to pricing pressures and reduced profit margins, impacting market sustainability.

• Data Interpretation and Analysis: The influx of data necessitates efficient and accurate data analysis methods, and the shortage of bioinformatics expertise can hinder progress.

• Ethical and Moral Issues: Ongoing debates on ethical dilemmas related to genetic testing, privacy, and consent can create uncertainties and potential public backlash.

• Funding and Budget Constraints: Economic downturns or budget limitations in research institutions and healthcare systems can limit investments in sequencing technologies and research projects.

• Intellectual Property Disputes: Patent disputes and intellectual property battles can disrupt product development and market entry, leading to legal complexities.

• Sample Quality and Preparation: Poor sample quality or inadequate preparation can result in inaccurate results, which can negatively impact the credibility of the technology.

• Emerging Competitors: New entrants and disruptive technologies can challenge established players, potentially reshaping the market dynamics.

Report Scope

Feature of the Report	Details
Market Size in 2023	USD 6.2 Billion
Projected Market Size in 2032	USD 91.1 Billion
Market Size in 2022	USD 5.08 Billion
CAGR Growth Rate	23.1% CAGR
Base Year	2023
Forecast Period	2024-2033
Key Segment	By Technology, Application, Type, End Use and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope	North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Technology:

• Sequencing: Sequencing is the core technology within the Targeted Sequencing and Resequencing Market, responsible for deciphering the precise sequence of nucleotide bases in DNA or RNA molecules. This process unlocks crucial genetic information. An ongoing trend in sequencing revolves around the constant refinement of Next-Generation Sequencing (NGS) techniques, resulting in quicker and more cost-efficient analysis, and enabling diverse applications in genomics research, clinical diagnostics, and personalized medicine. Furthermore, the emergence of single-molecule sequencing and long-read technologies is gaining traction, allowing for the accurate sequencing of intricate genomes and structural variations.

• Re-sequencing: Re-sequencing constitutes a subset of sequencing dedicated to comparing an organism’s DNA or RNA sequences with a reference genome. Its primary purpose is to pinpoint variations, mutations, or disparities between the sample and the reference. A prominent trend in re-sequencing centers on its expanding role in fields such as population genetics, cancer investigations, and evolutionary research. It plays an instrumental role in detecting disease-causing mutations and unraveling the genetic diversity within populations, contributing significantly to the advancement of precision medicine and the deepening of genomic insights across various scientific domains.

By Application

• Clinical Application: In the Targeted Sequencing and Resequencing Market, clinical applications involve the use of advanced genomic techniques to diagnose genetic disorders, detect mutations linked to diseases, and personalize treatment plans. Current trends include the integration of precision medicine into healthcare, expanded use in cancer diagnostics, and non-invasive prenatal testing. Continuous advancements in sequencing technologies and bioinformatics tools enhance the accuracy and efficiency of clinical applications.

• Plant and Animal Sciences: Within this market segment, plant and animal scientists utilize targeted sequencing and resequencing to unravel genetic mysteries in flora and fauna. Researchers employ these techniques to enhance crop breeding, preserve biodiversity, and improve livestock genetics. Trends encompass genome editing in agriculture, conservation efforts, and the quest for sustainable farming practices, fostering innovation and improved outcomes in these fields.

• Drug Development: In the context of drug development, targeted sequencing and resequencing play a pivotal role in identifying therapeutic targets, assessing drug responses, and optimizing clinical trials. The trends in this segment include the utilization of genomics for personalized medicine, accelerating drug discovery through genomic data, and tailoring treatments based on an individual’s genetic makeup. This contributes to more efficient drug development processes and better treatment outcomes.

• Others: The “Others” category encompasses various emerging applications beyond clinical, plant and animal sciences, and drug development. This may include forensic genomics, environmental DNA analysis, and studies of microbial communities. Trends in this segment can be diverse, reflecting evolving uses of targeted sequencing and resequencing in interdisciplinary research, which continually expands the boundaries of genomics applications.

By Type

• DNA-Based Targeted Sequencing: DNA-based targeted sequencing is a technique that homes in on specific sections of the DNA molecule, enabling the precise examination of genetic variations, mutations, and structural alterations. It plays a pivotal role in applications like precision medicine and the diagnosis of rare diseases. Present trends in DNA-based targeted sequencing involve its expanding utility in precision medicine, integration into the realm of cancer genomics, and the development of high-throughput platforms that enhance the speed and cost-effectiveness of DNA sequencing. Furthermore, advancements in data analytics tools and automation have elevated the precision and efficiency of DNA-based targeted sequencing.

• RNA-Based Targeted Sequencing: Conversely, RNA-based targeted sequencing centers on the analysis of specific RNA molecules, offering insights into gene expression, splice variants, and fusion genes. It’s gaining prominence in research pertaining to gene regulation, molecular biology, and the understanding of disease mechanisms. Current trends in RNA-based targeted sequencing encompass its growing use in transcriptomics and single-cell RNA sequencing, as well as the creation of techniques to capture RNA from limited samples. In addition, enhancements in library preparation kits and data analysis workflows have heightened the precision and depth of insights derived from RNA-based targeted sequencing, making it an invaluable tool in genomics research.

By End Use

• Hospitals & Clinics: In the Targeted Sequencing and Resequencing Market, hospitals and clinics utilize these technologies for clinical diagnostics, personalized treatment, and disease monitoring. They play a vital role in advancing precision medicine by identifying genetic variations, and enabling tailored therapies. The trend in this segment involves the integration of genomics into routine clinical practices, such as cancer diagnostics and non-invasive prenatal testing, enhancing patient care.

• Academic Research: Academic institutions leverage targeted sequencing and resequencing for diverse genomic studies. These include genetic research, evolutionary biology, and biodiversity assessments. The trend here is an increased focus on interdisciplinary collaborations, as academic researchers explore the broader implications of genomics in various scientific disciplines, promoting cross-disciplinary innovations.

• Others: The “Others” category typically encompasses pharmaceutical companies, biotechnology firms, and research organizations outside academia. These entities use targeted sequencing and resequencing for drug discovery, agriculture, and various specialized applications. A notable trend in this segment is the expanding applications of genomics, from agri-genomics to forensic studies, broadening the market’s scope and relevance across multiple sectors.

Targeted Sequencing and Resequencing Market – Regional Analysis

The Targeted Sequencing and Resequencing Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: North America is a leading region in the Targeted Sequencing and Resequencing Market, characterized by advanced healthcare infrastructure and research institutions. The trend here is a strong emphasis on precision medicine, particularly in the United States and Canada, with a growing focus on cancer genomics and rare disease diagnostics. Ongoing investments in genomics research and clinical applications drive innovation and market growth.

• Europe: Europe is a hub for genomics research and applications. The trend in this region involves increased collaboration between academic and industrial sectors, fostering advancements in personalized medicine and population genomics. European countries prioritize genomic data sharing and ethical considerations, contributing to robust growth in the market.

• Asia-Pacific: The Asia-Pacific region is witnessing rapid market growth, driven by increased healthcare spending, adoption of NGS technologies in research, and expanding clinical applications. The trend here is a surge in government initiatives and investment in genomics, particularly in countries like China, India, and Japan. Research and development in agriculture, cancer diagnostics, and infectious disease studies are among the driving forces.

• LAMEA: LAMEA is an emerging market in targeted sequencing and resequencing. The trend is characterized by the expansion of genomics applications in healthcare, agriculture, and biodiversity conservation. Governments in the Middle East and Africa are investing in genomics research, and Latin American countries are embracing precision medicine. The market in this region is poised for significant growth due to rising awareness and infrastructure development.

Competitive Landscape – Targeted Sequencing and Resequencing Market

The Targeted Sequencing and Resequencing Market is highly competitive, with a large number of manufacturers and Othersers operating globally. Some of the key players in the market include:

• Illumina Inc.
• Agilent Technologies
• Thermo Fisher Scientific Inc.
• Hoffmann-La Roche Ltd
• DNASTAR Inc.
• Bio-Rad Laboratories Inc.
• PacBio
• Integrated DNA Technologies Inc.
• RainDance Technologies Inc.
• Perkin Elmer Inc.
• BGI
• PierianDx
• Genomatix GmbH
• GATC Biotech Ag
• Macrogen Inc.
• QIAGEN
• Oxford Nanopore Technologies
• SRS Pharmacy Systems
• Others

These companies operate in the market through various strategies such as application innovation, mergers and acquisitions, and partnerships.

New players entering the Targeted Sequencing and Resequencing Market often focus on innovation and development to establish their presence. They leverage technologies like long-read sequencing and advanced data analysis tools. Companies like 10x Genomics and Twist Bioscience have gained prominence by introducing novel solutions.

Key players dominating the market are Illumina, Thermo Fisher Scientific, and Pacific Biosciences. They maintain their dominance by consistently innovating, offering comprehensive sequencing platforms, and fostering collaborations with academic and clinical institutions.

Illumina, in particular, maintains a strong market position with a wide product portfolio, including the NovaSeq series, and by expanding its presence in clinical diagnostics and research applications worldwide. These key players emphasize product reliability, scalability, and support to maintain their leadership.

The Targeted Sequencing and Resequencing Market is segmented as follows:

By Technology

• Sequencing
• Re-sequencing

By Application

• Clinical application
• Plant and animal sciences
• Drug development
• Others

By Type

• DNA-based targeted sequencing
• RNA-based targeted sequencing

By End Use

• Hospitals & clinics
• Academic research
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America